ARCHIVES

Ovarian Suppression Treatment Plus Tamoxifen Can Lower Recurrence Risk

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

Zometa Reduced Bone Complications In Patients With Prostate Cancer Bone Mets

October 25, 2002

NCI Is Considering New Core Grants For Prostate, Breast Research Centers

April 19, 1991

NCI Programs: Klausner Plans 20-25% Increase In Funding For Cooperative Groups

November 6, 1998

Dana-Farber And Merck To Collaborate On Therapeutics.

February 15, 2008

In Brief: Myers, Whang-Peng, Zink Leaving NCU; FDA Hires New Legislative Affairs Chief

February 18, 1994

FDA News: Zydelig approved in three B-cell blood cancers

August 1, 2014